RUBRYC THERAPEUTICS
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs. RubrYc Therapeutics using disruptive innovation to deliver fresh insights into the design and development of therapeutic antibodies. Inspired by recent advancements in molecular library synthesis, massively parallel screening and computing, they are forging a new path for information-driven discovery of therapeutic antibodies.
RUBRYC THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2017-01-01
Address:
San Ramon, California, United States
Country:
United States
Website Url:
http://www.rubryc.com
Total Employee:
11+
Status:
Active
Total Funding:
17.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Google Tag Manager Font Awesome Apache Microsoft Exchange Online Amazon
Similar Organizations
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
Primmune Therapeutics
Primmune Therapeutics is a Biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
iBio
iBio investment in Series A - RubrYc Therapeutics
Vital Venture Capital
Vital Venture Capital investment in Series A - RubrYc Therapeutics
Hayan Health Networks
Hayan Health Networks investment in Series A - RubrYc Therapeutics
Third Point Ventures
Third Point Ventures investment in Series A - RubrYc Therapeutics
Paladin Capital Group
Paladin Capital Group investment in Series A - RubrYc Therapeutics
Official Site Inspections
http://www.rubryc.com Semrush global rank: 4.8 M Semrush visits lastest month: 1.91 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "RubrYc Therapeutics"
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery …
Sep 21, 2022 · RubrYc’s Discovery Engine enabled the rapid identification of antibodies that selectively bind the mutated protein, without binding the wild-type version, which is more commonly expressed in healthy tissues.See details»
RubrYc Therapeutics - Crunchbase Company Profile & Funding
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody …See details»
RubrYc - VentureRadar
Website: http://www.rubryc.com/ Develops machine-learning and computational biology solutions to discover epitope-selective biotherapeutics using Meso-scale Engineered Molecules (MEMs) …See details»
RubrYc Therapeutics Company Profile 2024: Valuation, …
May 1, 2019 · Developer of novel biotherapeutic technologies designed to integrate chemistry and computation to discover and develop antibody-based drugs with epitope selectivity.See details»
RubrYc Therapeutics, Inc. Company Profile | San Carlos, CA ...
Find company research, competitor information, contact details & financial data for RubrYc Therapeutics, Inc. of San Carlos, CA. Get the latest business insights from Dun & Bradstreet.See details»
iBio acquires RubrYc Therapeutics - 2022-09-21 - Crunchbase
Sdbn.org — CDMO makes an AI and drug discovery play in latest, small-time acquisitionSee details»
iBio acquires RubrYc Therapeutics' AI drug discovery …
Sep 21, 2022 · AI drug discovery platform: A patented system that uses artificial intelligence (AI) to design 3D models of epitopes to facilitate the creation of better antibody drug candidates.See details»
iBio - Epitope-Steering and Antibody Optimization
Learn how we are deploying our AI Drug Discovery Platform to develop a robust immuno-oncology pipeline. Where collaboration fuels breakthroughs in drug discovery. Press Releases. See iBio's latest press releases. Meet us at the …See details»
iBio Acquires RubrYc Therapeutics' AI Drug ... - Drug Discovery …
Sep 21, 2022 · Bio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, …See details»
Nature-inspired, antibody discovery driven by AI
Biotechnology company RubrYc Therapeutics, Inc., founded in 2017, has developed a proprietary machine learning-driven solution for the discovery of best-in-class and first-in-class...See details»
RubrYc Therapeutics Company Profile - Office Locations ... - Craft
RubrYc Therapeutics is a biotechnology solutions company that provides insights into the design and development of therapeutic antibodies. It offers the RubrYc Discovery Engine that can …See details»
RubrYc Therapeutics - Funding, Financials, Valuation & Investors
RubrYc Therapeutics is funded by 5 investors. iBio and Vital Venture Capital are the most recent investors. RubrYc Therapeutics has a post-money valuation in the range of $10M to $50M as …See details»
Nature-inspired, antibody discovery driven by AI
Biotechnology company RubrYc Therapeutics, Inc., founded in 2017, has developed a proprietary machine learning-driven solution for the discovery of best-in-class and first-in-class...See details»
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery
Sep 21, 2022 · AI Drug Discovery Platform: A patented system that uses artificial intelligence (“AI”) to design 3D models of epitopes to facilitate the creation of better antibody drug candidates.See details»
iBio acquires multiple assets of AI drug discovery partner RubrYc
Sep 27, 2022 · iBio is jockeying for position as a leading player in AI-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple …See details»
RubrYc Therapeutics Announces formation of its Scientific …
SAN CARLOS, Calif., Dec. 4, 2019 /PRNewswire/ -- RubrYc Therapeutics, Inc., a pre-clinical company developing therapeutic antibodies for the treatment of cancer and autoimmune …See details»
RubrYc Therapeutics Announces Series A2 Preferred Equity …
Aug 25, 2021 · With this transaction, iBio becomes an important strategic investor with its $7.5M investment in the RubrYc’s Series A2 Preferred equity, joining Third Point Ventures, Paladin …See details»
RubrYc Therapeutics - Contacts, Employees, Board Members
RubrYc Therapeutics has 2 current employee profiles, including Co Founder & CEO Isaac Bright. RubrYc Therapeutics has 1 board member or advisor, Tom Isett.See details»
RubrYc Therapeutics To Present at AACR Virtual Conference
Jun 23, 2020 · SAN CARLOS, Calif.-- ( BUSINESS WIRE )--RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes …See details»
RTX-002 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 · RTX-002: a PD-1 agonists Drug, Initially developed by RubrYc Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Mechanism: PD-1 agonists (Programmed cell …See details»